4,7-dichloroindole-2-carboxylic acid | 96129-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,7-dichloroindole-2-carboxylic acid
• 英文别名: 4,7-dichloro-1H-indole-2-carboxylic acid；4,7-Dichlor-indol-2-carbonsaeure
• CAS: 96129-74-7
• 化学式: C₉H₅Cl₂NO₂
• mdl: MFCD02664446
• 分子量: 230.05
• InChiKey: LMYQVAQDBJJBEM-UHFFFAOYSA-N

物化性质

• 沸点：
  473.7±40.0 °C(Predicted)
• 密度：
  1.663±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,7-dichloroindole-2-carboxylic acid 在 喹啉 、 铜 作用下， 反应 1.0h， 以81.5%的产率得到4,7-二氯吲哚
  参考文献：
  名称：

  Solution and flash vacuum pyrolysis of some 2,6-disubstituted .beta.-phenethylsulfonyl azides and of .beta.-styrenesulfonyl azide

  摘要：

  DOI：

  10.1021/jo00212a013
• 作为产物：
  描述：

  2-(2,5-dichloro-phenylhydrazono)-propionic acid 在 PPA 、 alkaline solution 、 硫酸 作用下， 生成 4,7-dichloroindole-2-carboxylic acid
  参考文献：
  名称：

  Pappalardo; Vitali, Gazzetta Chimica Italiana, 1958, vol. 88, p. 1147,1153, 1159

  摘要：

  DOI：

文献信息

• [EN] INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDOLE CARBOXAMIDE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2014037900A1

  公开（公告）日：2014-03-13

  A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

  提供了一种化合物，其化学式为（I），已被证明对治疗通过mmpL3途径中的必需分子的运输介导的疾病、紊乱或综合症具有益处：（I）其中R1、R2、R3、R4、R5和R6如本文所定义。
• New indole derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20030199689A1

  公开（公告）日：2003-10-23

  The present invention relates to compounds of formula I, 1 in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; R 7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R0；R1；R2；R3；R4；R5；R6；R7；Q；V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者在其治疗或预防需要抑制因子Xa和/或因子VIIa的情况下。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为用于治疗上述疾病的药物，以及包含它们的制剂。
• Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites
  作者：Alex R. Maolanon、Rune Risgaard、Shuang-Yan Wang、Yoran Snoep、Athanasios Papangelis、Feng Yi、David Holley、Anne F. Barslund、Niels Svenstrup、Kasper B. Hansen、Rasmus P. Clausen

  DOI：10.1021/acschemneuro.7b00117

  日期：2017.8.16

  superagonists at the GluN1 subunit with agonist efficacies of 398% and 308% compared to glycine. This study demonstrates that subunit-selectivity among glycine site NMDA receptor agonists can be achieved and suggests that glycine-site agonists can be developed as pharmacological tool compounds to study GluN2C-specific effects in NMDA receptor-mediated neurotransmission.

  设计了一系列基于丝氨酸为先导结构的类似物，并使用两电极电压钳（TEVC）电生理学对重组NMDA受体亚型（GluN1 / 2A-D）的激动剂活性进行了评估。以依赖于NMDA受体中的GluN2亚基的方式观察到亚基选择性，效力和激动剂功效的明显变化。特别是化合物15a和16a是在GluN1亚基上有效的GluN2C特异性超激动剂，与甘氨酸相比，激动剂的效率为398％和308％。这项研究表明，可以实现甘氨酸位点NMDA受体激动剂之间的亚基选择性，并建议可以开发出甘氨酸位点的激动剂作为药理工具化合物，以研究NMDA受体介导的神经传递中GluN2C的特异性作用。
• NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：NAZARE Mark

  公开号：US20090069565A1

  公开（公告）日：2009-03-12

  The present invention relates to compounds of formula I, in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; R 7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0; R1; R2; R3; R4; R5; R6; R7; Q; V，G和M具有声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可以应用于存在因子Xa和/或因子VIIa不良活性的情况，或者治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为治疗上述疾病的药物以及包含它们的制药制剂。
• INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF
  申请人：Jiricek Jan

  公开号：US20150175539A1

  公开（公告）日：2015-06-25

  A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein.

  提供一种化合物，其化学式为（I），已被证明可用于治疗由mmpL3途径中必需分子的运输介导的疾病、障碍或综合症：其中R1、R2、R3、R4、R5和R6如此定义。